Day: July 11, 2023

Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and DurationKANSAS CITY, Kan., July 11, 2023 (GLOBE NEWSWIRE)...

Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women

Sildenafil Cream Demonstrated Statistically Significant Improvement in Sexual Desire, an Exploratory Endpoint; Improvements in Arousal Lubrication, Orgasm and Sexual Desire...

Recce Pharmaceuticals Announces First Cohort Dosed in RECCE® 327 Rapid Infusion Phase I/II Urinary Tract Infection (UTI) Clinical Trial

Highlights: First cohort in Phase I/II urinary tract infection (UTI) rapid infusion intravenous (IV) study successfully dosed 2,500mg of RECCE®...

Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program

Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer

Proprietary T-Bolt™ technology dramatically broadens the benefits of immunotherapy by targeting the entire universe of cancer antigens  Company led by proven industry...

ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients

AccuStem Sciences, Inc. Extends and Broadens Partnership with Instituto Europeo di Oncologia (IEO) Enabling its Strategic Approach to Address Unanswered Clinical Questions in Early Stage Breast Cancer

StemPrintER outperformed the current market leader, OncotypeDX test, in stratifying patients according to their risk of breast cancer recurrenceLONDON and...

error: Content is protected !!